Description and management of cutaneous side effects during cetuximab or erlotinib treatments: A prospective study of 30 patients - 09/08/11

Doi : 10.1016/j.jaad.2006.04.062

Esther Roé, MD ^a,^⁎ , María Pilar García Muret, MD ^a, Eugenio Marcuello, MD ^b, Jaume Capdevila, MD ^b, Cinta Pallarés, MD ^b, Agustín Alomar, MD ^a
^a From the Departments of Dermatology
^b Oncology, Hospital de la Santa Creu i Sant Pau

Reprint requests: Esther Roé, MD, Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Sant Antoni Maria, Claret 167, 08025 Barcelona, Spain.

Barcelona, Spain

Abstract

Background

Drugs such as cetuximab or erlotinib, which inhibit the epidermal growth factor receptor, are increasingly being used in treatment of solid tumors. This has led to the appearance of new secondary effects.

Objective

We sought to describe the cutaneous side effects and their management in patients with cancer treated with cetuximab or erlotinib.

Methods

We clinically examined 30 patients determining type, frequency, treatment, and evolution of side effects.

Results

Most patients presented with a cutaneous reaction consisting of a follicular eruption, typically appearing in seborrheic areas within the first 15 days of treatment. Painful fissures in palms and soles and paronychia were the second most common cutaneous toxicities. We also noticed an alteration in hair growth at several months’ follow-up. As these secondary effects responded well to treatment, few patients discontinued the antineoplastic therapy because of cutaneous toxicity.

Limitations

This was a prospective but uncontrolled study.

Conclusion

Although these new targeted therapies have low systemic toxicity because of their high specificity, cutaneous side effects are common and may be serious.

Le texte complet de cet article est disponible en PDF.

Abbreviations used : EGFR, PD, PR, SD